^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    4d
    PROTECT: A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, Fudan University
    New P2 trial
    5d
    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2026 --> Sep 2028 | Trial primary completion date: Aug 2026 --> Sep 2028
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Promacta (eltrombopag)
    8d
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2027 --> Sep 2030 | Initiation date: Nov 2026 --> Jun 2026 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    8d
    Multiome-based identification of molecular markers for prospective identification of platelet-biased HSCs. (PubMed, Stem Cell Reports)
    In contrast, romiplostim treatment increased MUL-HSC prevalence. Finally, using spectral flow cytometry to simultaneously quantify cell cycle and HSC lineage bias, we show that platelet depletion selectively activates PLT-HSCs. Together, these approaches allow accurate isolation of PLT-HSCs and robust quantification of lineage bias under perturbation.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF18 (TNF Receptor Superfamily Member 18)
    |
    Nplate (romiplostim)
    14d
    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (clinicaltrials.gov)
    P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended
    Trial suspension • Tumor mutational burden
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation • Chr del(5q)
    |
    Promacta (eltrombopag)
    21d
    Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances. (PubMed, Ann Hematol)
    Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.
    Review • Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    STAT3 mutation
    |
    Jakafi (ruxolitinib) • Promacta (eltrombopag) • cyclosporin A microemulsion
    22d
    Romiplostim for Oral TPO-RA Resistant ITP (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    Nplate (romiplostim)
    28d
    Avatrombopag for Severe Thrombocytopenia After Liver Transplantation: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=134, Completed, Shanghai Zhongshan Hospital
    New trial
    1m
    ITJ(QN)2510: A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia (clinicaltrials.gov)
    P1, N=280, Not yet recruiting, Shanghai 10th People's Hospital
    New P1 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals
    New trial • HEOR • Real-world evidence
    |
    Promacta (eltrombopag)
    1m
    N01-A-PICIT-GT: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    N01-A-PICIT-GI: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)